The Growing Epidemic of Diabetes Mellitus

Lović, Dragan; Piperidou, Alexia; Zografou, Ioanna; Grassos, H.; Pittaras, Andreas; Manolis, Athanasios

doi:10.2174/1570161117666190405165911

Cited by 226 publications

(112 citation statements)

References 50 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…The possible explanation is that young patients with PDR usually experience more severe DR and a higher rate of blindness as demonstrated in previous study. [33] For the epidemiology aspect, DM influences about 5.7 percent of global population, [34] while the prevalence increases to 10.3 percent in the one Asian population. [35] Among those individuals with DM, the gross prevalence of DR is about 24.7 percent in a similar population.…”

Section: Discussionmentioning

confidence: 99%

The elevated risk of sight-threatening cataract in diabetes with retinopathy: a cohort study

Nien

Lee

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To survey the effect of diabetic retinopathy (DR) on the development of sight-threatening cataract via National Health Insurance Research Database of Taiwan.Methods Patients diagnosed with diabetes mellitus (DM) and DR were enrolled in the study group. The age and gender-matched DM individuals without DR and patients without DM served as the DM control group and non-DM control group, both with 1:4 ratios. The outcome was set as the performance of cataract surgery. Cox proportional hazard regression was used to calculate the adjusted hazard ratio (aHR) of DR with considering multiple factors of cataract formation.Results A total of 3,297 DR patients, 13,188 DM control patients and 13,188 non-DM controls were enrolled. There were 919 events (27.87 percent) of sight-threatening cataract in the study group while another 1,108 events (8.40 percent) in the DM control group and 957 events (7.26 percent) in the non-DM control group. After multivariable analysis, the study group showed a higher aHR of cataract surgery (2.93, 95% CI: 2.60-3.30) and a higher cumulative probability of cataract surgery compared to both the DM control and non-DM control groups (both Log rank P<0.001). Besides, both the proliferative DR (3.90, 95% CI: 3.42-4.45) and non-proliferative DR (2.35, 95% CI: 2.08-2.65) subgroups showed a higher aHR of cataract surgery than the DM control group.Conclusion The presence of DR will increase the risk for development of sight-threatening cataract that surgery is warranted, and the effect is prominent in both the proliferative DR and non-proliferative DR.

show abstract

Section: Discussionmentioning

confidence: 99%

The elevated risk of sight-threatening cataract in diabetes with retinopathy: a cohort study

Nien

Lee

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Diabetes mellitus (DM) is a chronic disease that according to WHO affects >422 million people worldwide. 1 In addition to its great and increasing clinical relevance, DM also has an important economic impact. In Spain, it has been estimated that the direct costs associated with the disease may reach €5100 million, representing 8% of global public health expenditure.…”

Section: Introductionmentioning

confidence: 99%

Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus

Oyagüez

Merino-Torres

Brito

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionCompare cost of the interstitial liquid glucose flash monitoring (FM) system (FreeStyle Libre 2) versus self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes mellitus (T1DM) in Spain.Research design and methodsA model was developed to estimate, with the perspective of the Spanish health system, the annual costs associated with glucose monitoring and hypoglycemic events management in T1DM population, with multiple insulin daily doses (MDI). According to published evidence, rate of severe hypoglycemia (SHE) of 4.90 episodes per patient-year was applied. Reduction of SHE (58.6%) was modeled associated with FM use. Published rates of hospital care (20.2%) and subsequent admission (16%) were assumed for SHE. The daily consumption of strips and lancets was 9 in patients with SMBG (before and after 4 daily intakes and at bedtime) and 0.5 for FM users (according to IMPACT trial findings). Annual consumption of 26 FM sensors was considered (1 every 14 days). Unit costs (in € of 2019, excluding VAT) were obtained from literature and national databases. Sensitivity analyses (SA) were carried out to evaluate the model robustness.ResultsThe total annual cost/patient was €4437 for SMBG and €2526 for FM. The use of FM would be associated with an annual savings in the costs of monitoring and managing hypoglycemic events of €1911 per patient-year. In a hypothetical cohort of 1000 patients with T1DM MDI, FM could avoid in 1 year 4900 SHE, 93 hospitalizations for SHE. In addition, the use of FM would generate total savings of up to €1 910 000 per year. In the SA with alternative hypoglycemia events rates and use of strips and lancets, and including non-SHE episodes, savings from €370 000 to €1 760 000 were observed with FM.ConclusionsThe use of the FM system to monitor glucose in adults with T1DM treated with MDI, would reduce hypoglycemic events and would result in cost savings for the health system.

show abstract

“…The prevalence of diabetes mellitus type 2 (T2DM) is globally increasing, and its complications are a significant health problem [1,2]. In 2014, over 422 million had diabetes, and a continuous rise in DM prevalence was expected [3].…”

Section: Introductionmentioning

confidence: 99%

Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial

et al. 2020

View full text Add to dashboard Cite

Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM. Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo (n = 30) and BP (n = 30). The supplementation was considered one 1000 mg capsule 2 times /day BP by meals (lunch and dinner) for 8 weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum nesfatin-1 level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed. Results: In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (P < 0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P > 0.05). Conclusion: BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results.

show abstract

The Growing Epidemic of Diabetes Mellitus

Cited by 226 publications

References 50 publications

The elevated risk of sight-threatening cataract in diabetes with retinopathy: a cohort study

The elevated risk of sight-threatening cataract in diabetes with retinopathy: a cohort study

Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus

Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial

Contact Info

Product

Resources

About